Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Blepharospasm Stories

2013-09-30 23:24:35

The U.S. Food & Drug Administration recently approved the use of Botox Cosmetic for the treatment of crow’s feet. Dr. Simon Ourian of Epione Beverly Hills says that physicians have been using Botox Cosmetic off-label for this purpose for years and that the practical impact will be minimal. Los Angeles, CA (PRWEB) September 30, 2013 On September 11, 2013, The U.S. Food and Drug Administration approved the use of onabotulinumtoxinA, marketed as Botox Cosmetic, to treat moderate to...

2013-09-19 23:31:47

Botox has been officially approved by the Food and Drug Administration to treat crow's feet, or wrinkles around the corners of the eyes. Park Ridge, IL (PRWEB) September 19, 2013 The U.S. Food and Drug Administration has finally approved the use of Botox Cosmetic for temporary improvement of moderate to severe lateral canthal lines, also known as crow’s feet. Allergan’s Botox Cosmetic injection is the first drug approved to treat the wrinkles that form on the outside edge of the...

FDA Approves Botox Anti-Wrinkle Treatments For Crow's Feet
2013-09-12 12:46:22

Lee Rannals for redOrbit.com - Your Universe Online Botox Cosmetic is an injected drug that was approved over a decade ago to treat frown lines, but plastic surgeons have been using it for a wide variety of other cosmetic purposes. And now, a US Food and Drug Administration ruling will allow the anti-wrinkling drug to be used for treating crow's feet. “This additional indication will provide people with a new FDA approved treatment option for those seeking a smoother appearance by...

2012-04-23 02:28:09

GREENSBORO, N.C., April 23, 2012 /PRNewswire/ -- Merz Pharmaceuticals today announced that initial baseline data from an ongoing Phase 4 Trial Evaluating XEOMIN® (incobotulinumtoxinA) for Cervical Dystonia (CD) and Blepharospasm in the United States (XCiDaBLE) will be presented at the 64th American Academy of Neurology (AAN) Annual Meeting in New Orleans, La. XEOMIN is approved for the treatment of cervical dystonia in adults, to decrease the severity of abnormal head position and neck...

2012-03-14 08:05:00

GREENSBORO, N.C., March 14, 2012 /PRNewswire/ -- Following a final hearing that occurred yesterday with the Honorable Andrew J. Guilford, the judge presiding over a recently concluded bench trial which focused on a commercial dispute over trade secrets, Merz is providing additional details on the outcome of the case. "We regret that this ruling will affect physicians and patients as we believe that access to quality FDA-approved treatment options, including XEOMIN®...

2012-01-04 09:38:00

GREENSBORO, N.C., Jan. 4, 2012 /PRNewswire/ -- Merz Pharmaceuticals, LLC, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific Healthcare Common Procedure Coding System (HCPCS) billing code, J0588 "INJECTION, INCOBOTULINUMTOXIN A, 1 UNIT" for Xeomin(®) (incobotulinumtoxinA), effective beginning January 1, 2012. The U.S. Food and Drug Administration (FDA) approved XEOMIN in July 2010 for the treatment of cervical dystonia in...

2011-12-23 17:10:00

Dr. Ingrid Warmuth is a specialist in many areas of dermatology and has been voted "Best Of The Best" by readers of the Vineland Daily Journal, and voted “Top Doc in South Jersey”. Elmer, New Jersey (PRWEB) December 23, 2011 Dr. Ingrid Warmuth is one of the selected providers for the early release of Xeomin. The Food and Drug Administration (FDA) recently approved this new botulinum toxin type A in July, 2011 for aesthetic indication; particularly to treat moderate to severe...

2011-11-17 11:30:00

FRANKFURT, Germany, Nov. 17, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that results from five studies examining XEOMIN® (incobotulinumtoxinA), a botulinum neurotoxin type A preparation free from accessory proteins, will be presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Orlando, Fla. The first poster being presented at the meeting, titled "Sustained efficacy of incobotulinumtoxinA...

2011-10-25 07:11:00

GREENSBORO, N.C., Oct. 25, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, today announced that data from studies evaluating the dosing and adverse event profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, in the treatment of blepharospasm (eyelid spasms) will be presented at the 115th Annual Meeting of the American Association of Ophthalmology (AAO) in Orlando, Fla. These data include an extension of the Phase III,...

2011-07-22 08:10:00

GREENSBORO, N.C., July 22, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, commends the Benign Essential Blepharospasm Research Foundation (BEBRF) for 30 years of dedication to increasing awareness of blepharospasm, a neurological disorder that causes abnormal, involuntary spasms of the muscles around the eye, and raising funds for research. Founded on July 23, 1981, BEBRF has grown to be an invaluable resource for the blepharospasm community. Many people living with blepharospasm have...